GlassScriptPhysician profile
Johnny Zhao
NPI 1447600697
$29,447.12
in general payments reported to CMS, 2019-2025
28 companies · $16K in 2025
The $16K reported for 2025 was more than what 93% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $371 · 2021: $751 · 2022: $1,430 · 2023: $2,362 · 2024: $8,739 · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,765 · Food and Beverage: $9,273 · Travel and Lodging: $3,933 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,713 · Education: $212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,765.00 |
| Food and Beverage | $9,272.58 |
| Travel and Lodging | $3,933.29 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,713.00 |
| Education | $211.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $17,313.68 | 2023-2025 | Tremfya, Simponi, Remicade |
| Abbvie INC. | $4,030.75 | 2020-2025 | Skyrizi, Rinvoq |
| Regeneron Healthcare Solutions, INC. | $990.50 | 2020-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $931.41 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $733.07 | 2021-2025 | Absorica Ld, Winlevi |
| Leo Pharma INC. | $662.56 | 2021-2025 | Adbry |
| Janssen Scientific Affairs, LLC | $636.98 | 2024-2025 | Tremfya |
| Incyte Corporation | $505.42 | 2021-2025 | Opzelura |
| Galderma Laboratories, L.P. | $451.76 | 2021-2025 | Nemluvio, Aklief, Oracea |
| Amgen INC. | $375.81 | 2020-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $296.43 | 2020-2024 | |
| Ucb, INC. | $287.86 | 2023-2025 | Bimzelx, Cimzia |
| Mayne Pharma Commercial LLC | $287.19 | 2020-2025 | |
| Pfizer INC. | $245.89 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $242.09 | 2022-2025 | Sotyktu |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $222.90 | 2023-2024 | Vtama |
| Lilly USA, LLC | $205.16 | 2020-2024 | Taltz, Olumiant |
| Arcutis Biotherapeutics, INC. | $185.83 | 2023-2025 | Zoryve |
| Allergan, INC. | $155.49 | 2020-2022 | |
| Almirall LLC | $138.82 | 2020-2023 | Seysara |
| Biofrontera INC. | $124.06 | 2021-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Journey Medical Corporation | $99.01 | 2022-2025 | |
| Botanix Sb INC | $98.27 | 2025 | Sofdra |
| Sanofi-Aventis U.S. LLC | $79.99 | 2021 | |
| Epi Health, LLC | $58.73 | 2020-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $44.73 | 2023-2025 | Cabtreo, Arazlo |
| Vyne Pharmaceuticals INC. | $25.20 | 2020 | |
| Organon LLC | $17.53 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Johnny Zhao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.